COVID‐19 Disease in Patients With Recurrent Pericarditis During Treatment With Anakinra: Comment on the Article by Navarro‐Millán et al

Objectives The systemic autoinflammatory diseases are rare conditions, to date data on COVID-19 infection and vaccination safety are scarce. Agents targeting innate immune pathways have transformed management of affected patients, and their outcomes are of wider interest given the role of inflammation in both viral clearance and severe COVID-19 disease. We surveyed patients with systemic autoinflammatory disease on biologic therapy to determine the prevalence and outcomes of COVID-19 infection and to gather early safety data on vaccination. Methods Electronic medical records of 248 patients with systemic autoinflammatory disease on biologic therapy at a national centre were reviewed. Patients were then surveyed in clinic or using a web-based survey. Results In the cohort of 248 patients, no deaths were recorded. 175 survey responses were received. Among the respondents, 27 reported suspected COVID-19 infection, of which 14 were confirmed by testing (8.0%). Two patients required admission due to dehydration. No patient required respiratory support or intensive care. 138 doses of COVID-19 vaccine had been administered to 130 patients. Side effects were reported following 71/138 (51.4%) administrations and were consistent with a flare of the underlying disease in 26/138 (18.8%) instances. No serious adverse events or hospital admissions were reported following vaccination. Conclusions These data, including the largest published series of patients on anti-Interleukin-1/6 biologics to receive any adenoviral vector or mRNA vaccine, show no serious early concerns regarding vaccination and will provide an urgently needed resource to inform decision making of these patients and their clinicians.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

COVID‐19 Disease in Patients With Recurrent Pericarditis During Treatment With Anakinra: Comment on the Article by Navarro‐Millán et al

Abstract: We read with interest the paper from Navarro‐Millan about the use of anakinra in severe COVID‐19 patients (1). On the other hand, there is the issue of patients treated with anakinra for their underlying condition and who develop COVID‐19 (2).

Cited by 3 publications

References 8 publications

Advances in pharmacotherapy for acute and recurrent pericarditis

Advances in pharmacotherapy for acute and recurrent pericarditis

Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease

COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics

Contact Info

Product

Resources

About